Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Haleon Plc on April 1, 2025, covering the month of April 2025. Haleon is a global leader in consumer health with a portfolio spanning Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals, and Supplements (VMS). The filing specifically addresses the company's total voting rights and capital structure as of March 31, 2025.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on share capital and voting rights.
Material Changes and Capital Structure
- Total Issued Shares: As of March 31, 2025, Haleon has 9,038,156,791 ordinary shares of £0.01 each.
- Treasury Shares: 4,080,205 shares are held as treasury shares.
- Voting Rights: The number of ordinary shares with voting rights is 9,034,076,586.
- Regulatory Use: This voting share count serves as the denominator for shareholders calculating notification obligations under the FCA's Disclosure Guidance and Transparency Rules.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document is a statutory notification of share capital.
Key Facts for Investor Verification
- Verify the denominator for disclosure thresholds is 9,034,076,586 voting shares.
- Confirm the total issued share count of 9,038,156,791 as of March 31, 2025.
- Note that this filing contains no financial performance data; refer to Form 20-F for quarterly or annual results.